Cite
HARVARD Citation
Moskowitz, A. et al. (2021). Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of clinical oncology. 39 (28), pp. 3109-3117. [Online].